BCL2 and cancer: Interestingly, prolonged exposure to CDDP led to a significant increase in RBBP6 expression in cancer cells, even in the presence of siRBBP6, suggesting a possible interaction between CDDP and RBBP6, as well as early insights into the possibility of RBBP6 acting in alliance during cisplatin-induced apoptosis via the wild-type p53 and Bcl-2 expression signature.